Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Neoplasms 13Carcinoma, Hepatocellular 7Carcinoma, Renal Cell 4Lymphoma 3Endometrial Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Lymphoma, Non-Hodgkin 2Liver Neoplasms 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Breast Neoplasms 2Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1

Interventions

pembrolizumab 26Nivolumab 18enfortumab vedotin 7avelumab 6atezolizumab 6Ipilimumab 6Magnetic Resonance Spectroscopy 5fludarabine 4cabozantinib 4Gemcitabine 4Cyclophosphamide 4Carboplatin 4Specimen Handling 3Interleukin-2 3Docetaxel 3130-nm albumin-bound paclitaxel 3aldesleukin 2Platinum 2Pemetrexed 2Paclitaxel 2Oxaliplatin 2Immunoglobulin G 2Fluorodeoxyglucose F18 2FAPI-46 2Disulfides 2Cisplatin 2Albumin-Bound Paclitaxel 2vinflunine 1veliparib 1valrubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Transitional Cell × lenvatinib × Clear all
NCT03006887 2021-05-20

Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors

Eisai Inc.

Phase 1 Completed
6 enrolled 27 charts
GenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡